In Vitro Activity of Anidulafungin against Selected Clinically Important Mold Isolates

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 5, 2004, Pages 1912-1915

  Odabasi, Zekaver ^a   Paetznick, Victor L ^a   Rodriguez, Jose R ^a   Chen, Enuo ^a   Ostrosky Zeichner, Luis ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BIPOLARIS SPICIFERA; DRUG EFFICACY; EXOPHIALA; EXOPHIALA JEANSELMEI; FONSECAEA PEDROSOI; FUNGUS; HYPHOMYCETES; MADURELLA; MINIMUM INHIBITORY CONCENTRATION; MOULD; NONHUMAN; PENICILLIUM MARNEFFEI; PETRIELLIDIUM BOYDII; PHIALOPHORA VERRUCOSA; PRIORITY JOURNAL; SPOROTHRIX SCHENCKII; WANGIELLA DERMATITIDIS;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; FUNGI; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 2142707210     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.5.1912-1915.2004     Document Type: Article

References (32)

1. Barry, A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459.
2. Consigny, S., N. Dhedin, A. Datry, S. Choquet, V. Leblond, and O. Chosidow. 2003. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient. Clin. Infect. Dis. 37:311-313.
3. Del Poeta, M., W. A. Schell, and J. R. Perfect. 1997. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. 41:1835-1836.
4. Denning, D., P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.
5. Deresinski, S., and D. Stevens. 2003. Caspofungin. Clin. Infect. Dis. 36:1445-1457.
6. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
7. Fleming, R. V., T. J. Walsh, and E. J. Anaissie. 2002. Emerging and less common fungal pathogens. Infect. Dis. Clin. N. Am. 16:915-933.
8. Fortun, J., P. Martin-Davila, M. Sanchez, V. Pintado, M. Alvarez, A. Sanchez-Sousa, and S. Moreno. 2003. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis. 22:408-413.
9. Herbrecht, R., D. Denning, T. Patterson, J. Bennett, R. Greene, J. Oestmann, W. Kern, K. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. Rubin, J. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. Chandrasekar, M. Hodges, H. Schlamm, P. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
10. Keating, G., and D. Figgitt. 2003. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs 63:2253-2263.
11. Klopfenstein, K., R. Rosselet, A. Termuhlen, and D. Powell. 2003. Successful treatment of Scedosporium pneumonia with voriconazole during AML therapy and bone marrow transplantation. Med. Pediatr. Oncol. 41:494-495.
12. Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960.
13. Lin, S. J., J. Schranz, and S. M. Teutsch. 2001. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32:358-366.
14. Marr, K. A., R. A. Carter, F. Crippa, A. Wald, and L. Corey. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34:909-917.
15. Morrison, V. A., R. J. Haake, and D. J. Weisdorf. 1993. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine (Baltimore) 72:78-89.
16. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard NCCLS document M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. Oakley, K. L., C. B. Moore, and D. W. Denning. 1998. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. 42:2726-2730.
18. Odds, F., A. Brown, and N. Gow. 2003. Antifungal agents: mechanisms of action. Trends Microbiol. 11:272-279.
19. Pacetti, S., and S. Gelone. 2003. Caspofungin acetate for treatment of invasive fungal infections. Ann. Pharmacother. 37:90-98.
20. Petraitiene, R., V. Petraitis, A. H. Groll, M. Candelario, T. Sein, R. Bell, C. A. Lyman, C. L. McMillian, J. Bacher, and T. J. Walsh. 1999. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother. 43:2148-2155.
21. Petraitis, V., R. Petraitiene, A. H. Groll, A. Bell, D. P. Callender, T. Sein, R. L. Schaufele, C. L. McMillian, J. Bacher, and T. J. Walsh. 1998. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42:2898-2905.
22. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255.
23. Pfaller, M. A., S. A. Messer, and S. Coffman. 1997. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. 41:763-766.
24. Ponton, J., R. Ruchel, K. V. Clemons, D. C. Coleman, R. Grillot, J. Guarro, D. Aldebert, P. Ambroise-Thomas, J. Cano, A. J. Carrillo-Munoz, J. Gene, C. Pinel, D. A. Stevens, and D. J. Sullivan. 2000. Emerging pathogens. Med. Mycol. 38:225-236.
25. Serrano Mdel, C., A. Valverde-Conde, M. M. Chavez, S. Bernal, R. M. Claro, J. Peman, M. Ramirez, and E. Martin-Mazuelos. 2003. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagn. Microbiol. Infect. Dis. 45:131-135.
26. Silveira, F., and M. Nucci. 2001. Emergence of black moulds in fungal disease: epidemiology and therapy. Curr. Opin. Infect. Dis. 14:679-684.
27. Uzun, O., S. Kocagöz, Y. Çetinkaya, S. Arikan, and S. Ünal. 1997. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. 41:1156-1157.
28. Verweij, P. E., K. L. Oakley, J. Morrissey, G. Morrissey, and D. W. Denning. 1998. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 42:873-878.
29. Vincent, A., J. Cabrero, J. Greene, and R. Sandin. 2003. Successful voriconazole therapy of disseminated Fusarium solani in the brain of a neutropenic cancer patient. Cancer Control 10:414-419.
30. Walsh, T., I. Lutsar, T. Driscoll, B. Dupont, M. Roden, P. Ghahramani, M. Hodges, A. Groll, and J. Perfect. 2002. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. 21:240-248.
31. Walsh, T. J., and A. H. Groll. 1999. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transplant Infect. Dis. 1:247-261.
32. Zhanel, G. G., J. A. Karlowsky, G. A. J. Harding, T. V. Balko, S. A. Zelenitsky, M. Friesen, A. Kabani, M. Turik, and D. J. Hoban. 1997. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob. Agents Chemother. 41:863-865.